Cantor Fitzgerald analyst Charles Duncan initiated coverage of GH Research (GHRS) with an Overweight rating and no price target GH Research is ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

He does not believe the drugs should be first-line treatment for obesity, echoing the views of several public health leaders — including former FDA commissioner Robert Califf. Tackling the U.S ...

(When the FDA first approved esketamine in 2019, it required people to also continue taking their oral antidepressants. That's still possible but no longer required.) For treatment-resistant ...

(Nature Reviews Gastroenterology & Hepatology) Subgroup analysis of the ATLANTIS trial of the antidepressant amitriptyline ... (Gut) The FDA granted tentative approval to a generic form of ...

An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

Antidepressants and other prescription drugs are subject to multiple, large clinical trials that evaluate safety and efficacy before they are approved. Additionally, the FDA has multiple systems ...

The US Food and Drug Administration (FDA) has approved the use of esketamine ... who have not responded adequately to at least two oral antidepressants. This decision expands the indication ...

The FDA has approved the use of Spravato, an antidepressant nasal spray, as a standalone treatment for depression in the U.S. Sue Varma discusses why she supports the use of the drug and how it ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...